Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Thrombosis‐related mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asymptomatic venous thromboembolism ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
First‐time symptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Major bleeding · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes venous thromboembolism‐related mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review
Quality of life ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asymptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Clinically relevant non‐major bleeding ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
First‐time symptomatic venous thromboembolism · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
1 finding from 1 review
Progression‐free survival · women with advanced or recurrent endometrial cancer
mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · women with advanced or recurrent endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer
mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).
1 finding from 1 review
Haematological toxicities ‐ Anaemia · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Skin toxicities ‐ Mucositis · women with advanced or recurrent endometrial cancer
mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Respiratory toxicity ‐ Interstitial pneumonitis · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review
Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer
mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).
1 finding from 1 review